Pembrolizumab-responsive PBMCs in the No pCR cohort.
Trastuzumab ADCC levels with and without pembrolizumab against SKBR3 cells using pre-treatment patient PBMCs from In addition, the pre-treatment PD-1 inhibited ADCC response (Fig. 